Find Funding Opportunities

Returning 788 results

Request for Information (RFI): Soliciting Input on Priorities and Progress in Alzheimer's Disease-Related Dementias Research

NOT
Monday, October 29, 2018
Friday, January 1, 2021
NOT-NS-19-011

Funding Opportunity Purpose

Request Information RFI): Soliciting Input Priorities Progress Alzheimer's Disease-Related Dementias Research Notice Number: NOT-NS-19-011 Key Dates Release Date: October 29, 2018 Response Date: December 20, 2018 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) National Institute Aging NIA) Purpose purpose this time-sensitive Request Information RFI) to seek input scientists, clinicians, patients, families, caregivers, advocates, the broader dementia community the most important needs promising opportunities Alzheimer's disease-related dementias ADRD) research.  Background The National Plan Address Alzheimer’s Disease, mandated the National Alzheimer's Project Act annually updated since 2012, includes goals the research, clinical care long-term services support are needed meet challenge addressing Alzheimer’s disease Alzheimer's disease-related dementias AD/ADRD).  Goal 1 the National Plan to prevent effectively treat Alzheimer’s disease related dementias 2025. help achieve goal, National Institutes Health NIH) convenes triennial summits develop recommendations advancing research AD ADRD.  Recommendations developed through summits become part the National Plan prioritized research milestones guide future NIH investments AD/ADRD research. May 2013, National Institute Neurological Disorders Stroke NINDS), collaboration the National Institute Aging NIA), convened first ADRD Summit, Alzheimer’s Disease-Related Dementias: Research Challenges Opportunities ADRD 2013) that established prioritized recommendations ADRD research.  March 2016, second ADRD Summit, Alzheimer's Disease-Related Dementias Summit 2016 ADRD 2016), assessed progress updated recommendations the 2013 Summit.  resulted a total 37 new revised research milestones for Lewy body dementia LBD), frontotemporal degeneration FTD), multiple etiology dementias MED), vascular contributions cognitive impairment dementia VCID), including recommendations cross-cutting topics such health disparities dementia dementia nomenclature. purpose this time-sensitive Request Information RFI) to seek input scientists, clinicians, patients, families, caregivers, advocates, the broader dementia community the most important needs promising opportunities Alzheimer's disease-related dementias ADRD) research.  information submitted response this RFI be used committees scientists, clinicians, other members the public revise update ADRD 2016 research recommendations.  draft recommendations be presented the public further input ADRD Summit 2019, will take place March 14-15, 2019, the main NIH campus Bethesda, MD.  Register attend ADRD 2019 at https://meetings.ninds.nih.gov/?ID=21149.  Registration free open the public.)  Information Requested National Institute Neurological Disorders Stroke invites interested stakeholders, including scientists, health professionals, patients, families, caregivers, advocacy groups, private sector, the general public, provide comments suggestions regarding ADRD research recommendations came of 2016 Summit became ADRD research milestones the National Plan Address Alzheimer's disease.  milestones be found at https://aspe.hhs.gov/alzheimers-disease-related-dementias-adrd-summit-2016-prioritized-research-milestones.  Information provide be used inform new revised research milestones will generated ADRD 2019. Please submit: comments suggestions regarding the current ADRD research milestones -- examples include comments how current milestones be revised, most promising areas research the research community should focus efforts based knowledge gap research needs, any new research questions draft recommendations should address based scientific progress we've since ADRD 2016, particular areas ADRD research the field made most progress on, etc. any research activities organization supported are alignment the ADRD research milestones, information the progress organization made towards milestones to Submit Response assure full consideration, responses must received December 20, 2018.  Responses this RFI must submitted via email to ADRD2019@ninds.nih.gov with ADRD Summit RFI" the subject line. Responses this RFI voluntary.  Submitted information not considered confidential.  Proprietary, classified, confidential, sensitive information should be included your response.  United States U.S.) Government reserves right use any non-proprietary technical information any resultant solicitation(s). RFI for planning purposes only is a solicitation applications an obligation the part the U.S. Government provide support any ideas identified response it.  Please note the U.S. Government not pay the preparation any comment submitted for use that comment.  NIH use information submitted response this RFI its discretion will provide individual feedback any responder. information provided be analyzed may appear reports. Inquiries Please direct inquiries to: Sophia Jeon, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-435-7571 Email: ADRD2019@ninds.nih.gov

Notice of Change to Application Due Date for Administrative Supplement for the NINDS Research Education Program for Residents and Fellow in Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (Admin Supplement)

NOT
Wednesday, October 24, 2018
Friday, January 1, 2021
NOT-NS-19-013

Funding Opportunity Purpose

Notice Change Application Due Date Administrative Supplement the NINDS Research Education Program Residents Fellow Neurosurgery, Neuropathology, Neuroradiology Emergency Medicine Admin Supplement) Notice Number: NOT-NS-19-013 Key Dates Release Date: October 24, 2018 Related Announcements PA-17-442 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform interested applicants there be change receipt dates the Funding Opportunity Announcement FOA) PA-17-442 "Administrative Supplement the NINDS Research Education Program Residents Fellows Neurology, Neurosurgery, Neuropathology, Neuroradiology, Emergency Medicine Admin Supp).  Specifically, October 15, 2018 receipt date been extended to November 2, 2018. Part 1. Overview Information Key Dates Currently Reads: Application Due Date(s) October 31, 2017, October 15, 2018 October 15, 2019 5:00PM local time applicant organization. Modified Read: Application Due Date(s) October 31, 2017, November 2, 2018, October 15, 2019 5:00PM local time applicant organization. other aspects this FOA remain same. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disease Stroke NINDS)) Telephone: 301-496-4188 Email: korns@ninds.nih.gov

Notice of Intent to Publish a Funding Opportunity Announcement for Translational Devices to Treat Pain (UG3/UH3 Clinical Trial Optional)

NOT
Tuesday, October 23, 2018
Friday, January 1, 2021
NOT-NS-19-009

Funding Opportunity Purpose

Notice Intent Publish Funding Opportunity Announcement Translational Devices Treat Pain UG3/UH3 Clinical Trial Optional) Notice Number: NOT-NS-19-009 Key Dates Release Date:October 23, 2018 Estimated Publication Date Funding Opportunity Announcement: November 15, 2018 First Estimated Application Due Date: December 15, 2018 Earliest Estimated Award Date: 15, 2018 Earliest Estimated Start Date: July 01, 2019 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) other NIH Institutes Centers participating the HEAL Helping End Addiction Long-term) Initiative, intends publish Funding Opportunity Announcement FOA) support development therapeutic, diagnostic, rehabilitative technologies pain. focus this FOA be support preclinical development demonstration safe, effective, non-addictive device-based technologies approaches treat pain. goal the program be demonstrate treatment using credible neural targets device-based interventions and/or diagnostics pain, building upon latest mechanistic knowledge the anatomy physiology central, spinal, peripheral pathways involved pain. FOA facilitate translation new devices overcoming key challenges identified during preliminary proof-of-concept studies. scope the program includes technology optimization, regulatory activities enable IDE/IRB approvals, a subsequent clinical study. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects. FOA expected be published 2018 an expected application due date 2018. FOA utilize UG3/UH3 activity code. Details the planned FOA provided below. Research Initiative Details Translational research develop new medical devices the focus this FOA. Applications this FOA should be hypothesis-driven, should propose design-directed technology development. Applications be expected have rigorous mechanistic biological rationale, scientifically sound assays test system, a near final device design. is also expected applications include supporting data the mechanism therapy, rehabilitation, diagnosis been demonstrated humans bench top, ex vivo, in silico, in vitro, and/or in vivo models representative the intended patient population indication. is anticipated there be restrictions invasiveness i.e., devices be non-invasive, minimally invasive, invasive). Devices utilize any viable modality focally interact the nervous system, such optical, electrical, magnetic, acoustic, chemical/pharmaceutical, microfluidic, combinations thereof. FOA not specific any pain condition patient population. Funding Information Estimated Total Funding Issuing IC partner components intend issue 5-7 awards 2019. Awards issued under FOA part funds set aside support HEAL Helping End Addiction Long-term) initiative. Expected Number Awards TBD Estimated Award Ceiling TBD Primary CFDA Numbers TBD Anticipated Eligible Organizations Public/State Controlled Institution Higher Education Private Institution Higher Education Nonprofit 501(c)(3) IRS Status than Institution Higher Education) Nonprofit without 501(c)(3) IRS Status than Institution Higher Education) Small Business For-Profit Organization than Small Business) State Government Indian/Native American Tribal Government Federally Recognized) County governments City township governments Special district governments Independent school districts Public housing authorities/Indian housing authorities Indian/Native American Tribally Designated Organization Native American tribal organizations than Federally recognized tribal governments) U.S. Territory Possession Indian/Native American Tribal Government than Federally Recognized) Non-domestic non-U.S.) Entity Foreign Organization) Regional Organization   Applications not being solicited this time.    Inquiries Please direct inquiries to: Nick Langhals, Ph.D. National Institute Neurological Disorders Stroke NINDS) 301-496-1447 Nick.Langhals@nih.gov  

Notice of Intent to Publish a Funding Opportunity Announcement for Translational Devices to Treat Pain (U44 Clinical Trial Optional)

NOT
Monday, October 22, 2018
Friday, January 1, 2021
NOT-NS-19-010

Funding Opportunity Purpose

Notice Intent Publish Funding Opportunity Announcement Translational Devices Treat Pain U44 Clinical Trial Optional) Notice Number: NOT-NS-19-010 Key Dates Release Date: October 22, 2018 Estimated Publication Date Funding Opportunity Announcement: November 15, 2018 First Estimated Application Due Date: November 15, 2018 Earliest Estimated Award Date: 15, 2019 Earliest Estimated Start Date: July 01, 2019 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) other NIH Institutes Centers participating the HEAL Helping End Addiction Long-term) Initiative, intends publish Funding Opportunity Announcement FOA) support development therapeutic, diagnostic, rehabilitative technologies pain. focus this FOA be support preclinical development demonstration safe, effective, non-addictive device-based technologies approaches treat pain. goal the program be demonstrate treatment using credible neural targets device-based interventions and/or diagnostics pain, building upon latest mechanistic knowledge the anatomy physiology central, spinal, peripheral pathways involved pain. FOA facilitate translation new devices overcoming key challenges identified during preliminary proof-of-concept studies. scope the program includes technology optimization, regulatory activities enable IDE/IRB approvals, a subsequent clinical study. Notice being provided allow potential applicants sufficient time develop meaningful collaborations responsive projects.  FOA expected be published 2018 an expected application due date 2018. FOA utilize U44 activity code. Details the planned FOA provided below. Research Initiative Details Translational research develop new medical devices the focus this FOA. Applications this FOA should be hypothesis-driven, should propose design-directed technology development. Applications be expected have rigorous mechanistic biological rationale, scientifically sound assays test system, a near final device design. is also expected applications include supporting data the mechanism therapy, rehabilitation, diagnosis been demonstrated humans bench top, ex vivo, in silico, in vitro, and/or in vivo models representative the intended patient population indication. is anticipated there be restrictions invasiveness i.e., devices be non-invasive, minimally invasive, invasive). Devices utilize any viable modality focally interact the nervous system, such optical, electrical, magnetic, acoustic, chemical/pharmaceutical, microfluidic, combinations thereof. FOA not specific any pain condition patient population. Funding Information Estimated Total Funding Issuing IC partner components intend issue 5-7 awards 2019. Expected Number AwardsTBD Estimated Award Ceiling TBD Primary CFDA Numbers TBD Anticipated Eligible Organizations Small Business Applications not being solicited this time.  nbsp; Inquiries Please direct inquiries to: Nick Langhals, Ph.D.National Institute Neurological Disorders Stroke NINDS)301-496-1447 Nick.Langhals@nih.gov Stephanie Fertig, MBA National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: fertigs@ninds.nih.gov  

Request for Information (RFI) on the Proposed Funding Priorities for Neuroscience Research, Input on Cross-Cutting Opportunities (NIH Neuroscience Blueprint)

NOT
Wednesday, October 17, 2018
Friday, January 1, 2021
NOT-NS-19-002

Funding Opportunity Purpose

Request Information RFI) the Proposed Funding Priorities Neuroscience Research, Input Cross-Cutting Opportunities NIH Neuroscience Blueprint) Notice Number: NOT-NS-19-002 Key Dates Release Date:October 17, 2018 Related Announcements None Issued NIH Blueprint Neuroscience Research ( http://neuroscienceblueprint.nih.gov) National Institute Neurological Disorders Stroke ( NINDS) National Eye Institute ( NEI) National Institute Aging ( NIA) National Institute Alcohol Abuse Alcoholism ( NIAAA) National Institute Biomedical Imaging Bioengineering ( NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development ( NICHD) National Institute Dental Craniofacial Research ( NIDCR) National Institute Drug Abuse ( NIDA) National Institute Environmental Health Sciences ( NIEHS) National Institute Mental Health ( NIMH) National Institute Nursing Research ( NINR) National Center Complementary Integrative Health ( NCCIH) Office Behavioral Social Sciences Research ( OBSSR)  Purpose National Institutes Health Blueprint Neuroscience Research Blueprint) a collaboration among 14 participating NIH Institutes, Centers Offices support cross-cutting funding programs advance research the nervous system. Request Information RFI) seeks input the scientific community future Blueprint activities. Responses this RFI should suggest best have broadest possible impact the neuroscience community, ideally, a value-added fashion over current activities the participating Institutes, Centers Offices. Recommendations should serve interests many the Blueprint Institutes listed above. Blueprint invites input all interested stakeholders. Organizations encouraged submit single representative response. Background Neuroscience research a unifying theme across NIH Institutes Centers. Sixteen participating Institutes Centers launched Blueprint 2004 provide framework coordinating research developing tools resources broadly advance neuroscience research. pooling resources expertise, NIH Blueprint taking advantage economies scale, confronting challenges too large any single NIH Institute Center IC), harmonizing related efforts across multiple ICs. following website provides overview previous current NIH Blueprint Activities: http://www.neuroscienceblueprint.nih.gov/. Information Requested Blueprint considering best advance neuroscience the future. the establishment funding the BRAIN Initiative, focuses development application innovative technologies interrogating circuit activity the nervous system, Blueprint hopes identify non-duplicative areas broad interest the neuroscience community will the highest potential advance neuroscience via investment cross-cutting research, training, infrastructure and/or workforce development. Keeping mind the Blueprint interested ideas are broadly relevant across multiple missions the 14 participating NIH Institutes Centers, comments the RFI include are limited the following areas: Please submit specific suggestions how NIH Blueprint enhance neuroscience training workforce diversity going forward. Please submit suggestions infrastructure research resources needs cut across NIH neuroscience Institutes Centers would best serviced a Blueprint program. addition to training diversity efforts, Blueprint previously supported programs address cross-cutting issues such as: computational neuroscience research, dissemination of neuroscience tools to advance science, supporting core facilities Please submit thoughts how efforts been useful.  Please submit suggestions specific ways which programs should expanded. Please identify specific scientific areas neuroscience research specific research topics are currently being supported the BP Institutes, Centers Offices would of broad interest impact. Please suggest level budgetary investment be needed make significant difference that research area over five-year period. Please identify specific impediments advancing our understanding neuroscience a Blueprint supported program solve. to Submit Response comments must submitted electronically to: NIH-Blueprint-Responses. Responses this RFI be accepted through November 26, 2018. will receive electronic confirmation acknowledging receipt your response will receive individualized feedback any suggestions. Disclaimer RFI is information planning purposes only should be construed a solicitation as obligation the part the Federal Government, National Institutes Health NIH), individual NIH Institutes Centers. NIH does intend make any awards based responses this RFI pay the preparation any information submitted for Government's of such information. basis claims against U.S. Government shall arise a result a response this request information from Government’s of such information. NIH use information submitted response this RFI its discretion will provide comments any responder’s submission. However, responses the RFI be reflected future planning activities funding opportunity announcements. information provided be analyzed may appear reports. Respondents advised the Government under obligation acknowledge receipt the information received provide feedback respondents respect any information submitted. proprietary, classified, confidential, sensitive information should included your response. Government reserves right use any non-proprietary technical information any resultant solicitation(s). Inquiries Please direct inquiries to: Meghan Mott, Ph.D. National Institute Neurological Disorders Stroke ( NINDS) Telephone: 301-596-4470 Email: nihblueprint@nih.gov

Notice of Clarification: Research Strategy page limit for PAR-18-548, Clinical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)

NOT
Monday, October 15, 2018
Friday, January 1, 2021
NOT-NS-19-005

Funding Opportunity Purpose

Notice Clarification: Research Strategy page limit PAR-18-548, Clinical Validation a Candidate Biomarker Neurological Disease U44 Clinical Trial Optional) Notice Number: NOT-NS-19-005 Key Dates Release Date:October 15, 2018 Related Announcements PAR-18-550 PAR-18-664 PAR-18-548 PAR-18-549 RFA-NS-18-046 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to clarify Research Strategy page limit PAR-18-548, Clinical Validation a Candidate Biomarker Neurological Disease U44 Clinical Trial Optional). Research Strategy section page limit been increased 12 20 pages allow additional space materials are disallowed the Appendix. Figures, tables, graphs, diagrams, data, charts are necessary support proposal should included the Research Strategy section, these not appropriate the Appendix. not the Appendix circumvent page limits. Allowable Appendix Materials, follow instructions the Appendix described the SF424 R&R) Application Guide. Allowable Appendix Materials restricted. Please the NIH Guide Notice on Allowable Appendix Materials and the FAQs the NIH Appendix Policy for information.  an application submitted disallowed materials the Appendix will withdrawn noncompliance. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Mary Ann Pelleymounter, PhD  National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779  Email:  mary.pelleymounter@nih.gov

Notice of Clarification: Research Strategy page limit for PAR-18-549, Analytical Validation of a Candidate Biomarker for Neurological Disease (U44 Clinical Trial Optional)

NOT
Monday, October 15, 2018
Friday, January 1, 2021
NOT-NS-19-008

Funding Opportunity Purpose

Notice Clarification: Research Strategy page limit PAR-18-549, Analytical Validation a Candidate Biomarker Neurological Disease U44 Clinical Trial Optional) Notice Number: NOT-NS-19-008 Key Dates Release Date:October 15, 2018 Related Announcements PAR-18-550 PAR-18-664 PAR-18-548 PAR-18-549 RFA-NS-18-046 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to clarify Research Strategy page limit PAR-18-549, Analytical Validation a Candidate Biomarker Neurological Disease U44 Clinical Trial Optional). Research Strategy section page limit been increased 12 20 pages allow additional space materials are disallowed the Appendix. Figures, tables, graphs, diagrams, data, charts are necessary support proposal should included the Research Strategy section, these not appropriate the Appendix. not the Appendix circumvent page limits. Allowable Appendix Materials, follow instructions the Appendix described the SF424 R&R) Application Guide. Allowable Appendix Materials restricted. Please the NIH Guide Notice on Allowable Appendix Materials and the FAQs the NIH Appendix Policy for information. If application submitted disallowed materials the Appendix will withdrawn noncompliance. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Mary Ann Pelleymounter, PhD  National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779  Email:  mary.pelleymounter@nih.gov

Notice of Clarification: Research Strategy page limit for PAR-18-550, Analytical Validation of a Candidate Biomarker for Neurological Disease (U01) (Clinical Trial Optional)

NOT
Monday, October 15, 2018
Friday, January 1, 2021
NOT-NS-19-007

Funding Opportunity Purpose

Notice Clarification: Research Strategy page limit PAR-18-550, Analytical Validation a Candidate Biomarker Neurological Disease U01) Clinical Trial Optional) Notice Number: NOT-NS-19-007 Key Dates Release Date:October 15, 2018 Related Announcements PAR-18-550 PAR-18-664 PAR-18-548 PAR-18-549 RFA-NS-18-046 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to clarify Research Strategy page limit PAR-18-550, Analytical Validation a Candidate Biomarker Neurological Disease U01) Clinical Trial Optional). Research Strategy section page limit been increased 12 20 pages allow additional space materials are disallowed the Appendix. Figures, tables, graphs, diagrams, data, charts are necessary support proposal should included the Research Strategy section, these not appropriate the Appendix. not the Appendix circumvent page limits. Allowable Appendix Materials, follow instructions the Appendix described the SF424 R&R) Application Guide. Allowable Appendix Materials restricted. Please the NIH Guide Notice on Allowable Appendix Materials and the FAQs the NIH Appendix Policy for information.  an application submitted disallowed materials the Appendix will withdrawn noncompliance. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Mary Ann Pelleymounter, PhD  National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779  Email:  mary.pelleymounter@nih.gov

Notice of Clarification: Research Strategy page limit for PAR-18-664, Clinical Validation of a Candidate Biomarker for Neurological Disease (U01 Clinical Trial Optional)

NOT
Monday, October 15, 2018
Friday, January 1, 2021
NOT-NS-19-006

Funding Opportunity Purpose

Notice Clarification: Research Strategy page limit PAR-18-664, Clinical Validation a Candidate Biomarker Neurological Disease U01 Clinical Trial Optional) Notice Number: NOT-NS-19-006 Key Dates Release Date:October 15, 2018 Related Announcements PAR-18-550 PAR-18-664 PAR-18-548 PAR-18-549 RFA-NS-18-046 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to clarify Research Strategy page limit PAR-18-664, Clinical Validation a Candidate Biomarker Neurological Disease U01 Clinical Trial Optional). Research Strategy section page limit been increased 12 20 pages allow additional space materials are disallowed the Appendix. Figures, tables, graphs, diagrams, data, charts are necessary support proposal should included the Research Strategy section, these not appropriate the Appendix. not the Appendix circumvent page limits. Allowable Appendix Materials, follow instructions the Appendix described the SF424 R&R) Application Guide. Allowable Appendix Materials restricted. Please the NIH Guide Notice on Allowable Appendix Materials and the FAQs the NIH Appendix Policy for information.  an application submitted disallowed materials the Appendix will withdrawn noncompliance. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Mary Ann Pelleymounter, PhD  National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779  Email:  mary.pelleymounter@nih.gov

Notice of Clarification: Research Strategy page limit for RFA-NS-18-046 Analytical and/or Clinical Validation of a Candidate Biomarker for Pain (R61/R33 Clinical Trial Optional)

NOT
Monday, October 15, 2018
Friday, January 1, 2021
NOT-NS-19-004

Funding Opportunity Purpose

Notice Clarification: Research Strategy page limit RFA-NS-18-046 Analytical and/or Clinical Validation a Candidate Biomarker Pain R61/R33 Clinical Trial Optional) Notice Number: NOT-NS-19-004 Key Dates Release Date:October 15, 2018 Related Announcements PAR-18-550 PAR-18-664 PAR-18-548 PAR-18-549  RFA-NS-18-046 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to clarify Research Strategy page limit RFA-NS-18-046, Analytical and/or Clinical Validation a Candidate Biomarker Pain R61/R33 Clinical Trial Optional). Research Strategy section page limit been increased 12 20 pages allow additional space materials are disallowed the Appendix. Figures, tables, graphs, diagrams, data, charts are necessary support proposal should included the Research Strategy section, these not appropriate the Appendix. not the Appendix circumvent page limits. Allowable Appendix Materials, follow instructions the Appendix described the SF424 R&R) Application Guide. Allowable Appendix Materials restricted. Please the NIH Guide Notice on Allowable Appendix Materials and the FAQs the NIH Appendix Policy for information.  an application submitted disallowed materials the Appendix will withdrawn noncompliance. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Mary Ann Pelleymounter, PhD  National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779  Email:  mary.pelleymounter@nih.gov

Pages